Search PubMed⌕ Search

Biomedical subjects

B G Simonsson

Publications and source records attributed to B G Simonsson.

At least 55 records · Page 3Linked to original sources
PubMed1980

Clinical implications of bronchial hyperreactivity.

Bronchial hyperreactivity may be a primary internal factor needed for the occurrence of asthmatic symptoms when the atopic individual meets with allergens or the non-atopic individual inhales irritants causing inflammatory reactions in the bronchial tree. It can also be a secondary expression of allergy and occupational exposures. The hyperreactivity can be affected by treatment and is therefore a valuable tool to judge experimental studies of background and predictive factors, for follow up of specified airways disease and for treatment and drug effects. It is necessary to collect sufficient background factors and to use proper dose-response studies. We still lack knowledge as to why presumed normal subjects react, is it due to undetected small airways disease? Do we need to measure both sensitivity (as threshold values) and reactivity (as dose response-curves) in all kinds of tests of bronchial reactivity? We need simple ways to test larger populations in prospective studies of workers exposed to occupational irritants in order to solve the problems of primary versus secondary, acquired hyperreactivity.

Allergens↗
PubMed1979

Treatment of recurrent pleural effusion by pleurodesis with quinacrine. Comparison between instillation by repeated thoracenteses and by tube drainage.

A total of 121 pleurodeses using instillations of quinacrine (mepacrine) in patients with recurrent pleural effusion were performed. All but three patients suffered from pleural malignancy. A comparison was made between the results achieved by repeated thoracenteses (73 cases) and by simultaneous tube drainage (48 cases). Tube drainage shortened the treatment and lowered the number of painful interventions. There was no difference in the quality of pleurodesis achieved by the two methods. The treatment failed in 12% of patients treated by repeated thoracenteses and in 14% of those treated by tube drainage. Patients with pleurodeses survive longer than non-treated subjects and have a considerably better quality of life.

Drainage↗
PubMed1976

Bilateral pulmonary aspergilloma in ankylosing spondylitis treated with transthoracic intracavitary instillations of antifungal agents.

Repeated transthoracic intracavitary injections of amphotericin B, nystatin and pimaricine proved a simple and safe method in the treatment of bilateral pulmonary aspergillomas in a patient with large cavities caused by lung disease in ankylosing spondylitis. Both large mycetomas were dissolved by this treatment in combination with peroral corticosteroid medication, and the patient's general condition improved markedly.

Amphotericin B↗
PubMed1976

Bronchodilatory and circulatory effects of two doses of a beta2-agonist (terbutaline) inhaled with IPPB in patients with reversible airways obstruction.

A beta2-receptor agonist, terbutaline (Bricanyl), in doses of 2.5 and 5 mg was inhaled by IPPB with a Bird Mark 8 in a double-blind cross-over randomized study on consecutive days in 12 patients with at least 15% reversibility of PEFR or FEV 1.0. One minute after the inhalation of 2.5 mg, PEFR had increased significantly; the greatest effect (+ 34%) was recorded after 120 min. After 5 mg the increase was more marked, with the greatest recorded effect (+ 43%) after 120 min; FEV1 and VC showed similar changes with a tendency towards greater and longer effects after the larger dose. Heart rate did not change. Systolic and diastolic blood pressures decreased at the most with 9 and 5 mmHg respectively, 30 min after 5 mg terbutaline. One patient reported tremor and palpitations 5 min after inhaling 5 mg. Our patients who were treated with beta-adrenergic drugs showed less systemic effects after the same dose of terbutaline than previously non-treated normal subjects in an earlier study. This may support recent findings of drug-induced tolerance to beta-stimulating agents in the heart and skeletal muscles with preservation of good effect on the airway smooth muscles, here shown as having a good residual bronchodilatory effect with clinically non-important effects on heart rate and tremor.

Adult↗
PubMed1975

Bronchodilatory and circulatory effects of inhaling increasing doses of an anti-cholinergic drug, ipratropium bromide (SCH 1000).

Dynamic spirometry with flow-volume curves and measurement of static lung volumes in a body plethysmograph were done in 11 patients with reversible airways obstruction before and up to 240 min after inhalation of 20 mug SCH 1000 and of another 40 mug 60 min later. Forced expiratory volume in 1 s (FEV1), vital capacity (VC) and maximal expiratory flow at 50% VC (V 50% VC) increased successively, reaching maximum after 120 min. In a second part of the study 13 patients inhaled 2+4+8 puffs of SCH 1000 (280 mug in all) at 30-min intervals. PEFR increased significantly up to 224 l/min (44% of predicted normal), with increasing number of SCH 1000 inhalations; no further general effect occurred after additional 3 puffs of terbutaline. Heart rate and blood pressure showed no clinically significant changes. No subjective or objective side-effects were noted.

Adult↗